Diagnostic and prognostic considerations for use of natriuretic peptides in obese patients with heart failure

Shruti Singh, Ambarish Pandey, Ian J. Neeland

Research output: Contribution to journalReview articlepeer-review

Abstract

Natriuretic peptides (NPs, B-type natriuretic peptide /BNP and NT-proBNP) are universally used biomarkers with established cut-points to aid in the diagnosis of heart failure (HF). It has been demonstrated that an inverse relationship exists between obesity, defined by the body mass index (BMI), and NPs, such that the application of NPs to diagnostic algorithms in HF remains challenging in overweight and obese patients. Some have advocated that lowering the cut-offs for NPs or using a correction for high BMI may improve the diagnostic accuracy in obese individuals. The inverse relationship of NPs with high BMI is present in both HF with reduced (HFrEF) and with preserved (HFpEF) ejection fraction, although levels tend to be higher in HFrEF. Nevertheless, data from several studies have shown that the prognostic value of NPs is preserved across BMI classes, and that increasing circulating levels of NPs correlate with adverse outcomes including all-cause mortality and HF hospitalizations. While NPs can still be used in diagnosis of HF in obese individuals, lower thresholds and the clinical context should be utilized in decision making. Additionally, given the validated prognostic value even in obesity, NPs can be employed in risk-stratification of individuals with obesity and HF, although there remains limited evidence about use in those with severe obesity (BMI >40 kg/m2).

Original languageEnglish (US)
Pages (from-to)649-655
Number of pages7
JournalProgress in Cardiovascular Diseases
Volume63
Issue number5
DOIs
StatePublished - Sep 1 2020

Keywords

  • B-type natriuretic peptide
  • Heart failure
  • Natriuretic peptides
  • Obesity

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Diagnostic and prognostic considerations for use of natriuretic peptides in obese patients with heart failure'. Together they form a unique fingerprint.

Cite this